ASH 2018 | Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant
CD19-directed CAR T-cells have demonstrated high responses in CD19+ acute lymphoblastic leukemia (ALL). Here, the long-term follow-up of the pediatric and young adult ALL patients after SCRI-CAR19v1 treatment in the PLAT-02 trial (NCT02028455) is presented, including the leukemia-free survival (LFS) of patients who proceeded to hematopoietic cell transplant (HCT) following remission after the CAR T-cell therapy. Corinne Summers, MD, of Seattle Children’s Research Institute, Seattle, WA, highlights how there was a trend towards improved LFS for patients without a prior history of HCT, and that HCT benefitted patients who attained complete remission but were at increased risk of relapse with short-term B-cell aplasia. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up